ADAMTS13 and COVID-19: Generally, the proteome of EVs in COVID-19 shows abnormalities, such as complement activation and platelet hyperreactivity [46], and increased loads of vWF, UPAR, and ADAMTS13 that correlates with higher levels of the thrombotic marker, D-dimer, and increased disease severity.